The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).
Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases
- Thread starter Educator
- Start date